Oncological Care During First Peruvian National Emergency COVID-19 Pandemic: A Multicentric Descriptive Study

Valdiviezo, N; Alcarraz, Cindy; Castro, Denisse; Salas, R; Begazo-Mollo, V; Galvez-Villanueva, M; Marianela, Medina Aguirre Luz; Garcia-León, E; Quispe-Santivañez, I; Cornejo-Raymundo, C; Paz-Cornejo, E; Sanchez-Vilela, L; Bermudez-Alfaro, V; JC, Vargas-Nina; Pérez-Ramos, C; Meza-Hoces, A; Barreto, Paolo R Valdez; Huaringa-Leiva, R; Muro-Cieza, J; Aguilar-Vásquez, V; EY, Cuenca; Neciosup-Delgado, Silvia; Poma-Nieto, N; Chavez-Gavino, S; Fernandez-Rosas, L; JM, Araujo; Payet, Eduardo; HL, Gomez

doi:10.2147/cmar.s350038

Cited by 6 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The COVID-19 pandemic has posed pressing challenges in providing health care to cancer patients (1).Due to lockdowns, a large part of screening and diagnosis has had to be postponed (2,3). During the pandemic, the cancer mortality rate was higher than that of the new coronary pneumonia (4), and an advanced clinical stage and treatment interruption were risk factors (5).…”

Section: Introductionmentioning

confidence: 99%

Effects of the COVID-19 pandemic on elderly patients with head and neck squamous cell carcinoma

Yan

Sun

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundThe 2019 novel coronavirus disease (COVID-19) strongly affects health care activities in countries around the world. The diagnosis and treatment of cancer have also been involved, and elderly head and neck squamous carcinoma is one of them. This study aimed to assess the impact of COVID-19 on elderly patients with head and neck squamous cell carcinoma (HNSCC) in our center.MethodsThis retrospective study analyzed the clinical characteristics of 400 HNSCC patients over 65 years of age, calculated their treatment interruption rates, and compared the time of delayed diagnosis.ResultsThe rate of elderly patients with HNSCC with a delayed diagnosis was higher in the “during COVID-19 pandemic” group (DCOV19 group) than in the “during COVID-19 pandemic” group (BCOV19 group), and the difference was statistically significant (p=0.0017). There was a substantial difference in the rate of treatment interruption between the two groups (p=0.002).ConclusionsThis is the first study to explore the effect of the COVID-19 pandemic on visits and treatment interruptions in elderly patients with HNSCC. The current impact of the COVID-19 pandemic on HNSCC treatment has resulted in reductions and delays in diagnosing cancer and providing treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of the COVID-19 pandemic on elderly patients with head and neck squamous cell carcinoma

Yan

Sun

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…An analysis of patients diagnosed and treated at the Instituto Nacional de Enfermedades Neoplasicas (INEN) has shown that 35.9% of BC patients were stages III or IV at diagnosis in 2000-2002; that figure did not significantly change in the 2010-2012 period, where 36.7% were diagnosed with advanced BC [22,23]. However, a recent study, conducted during the COVID-19 pandemic, has shown that 55.4% of cancer patients diagnosed and treated during 2019-2020 had an advanced stage [24]. In addition to the negative impact of COVID-19, the Peruvian healthcare system's inequities have worsened BC early detection.…”

Section: Discussionmentioning

confidence: 99%

A nationwide pilot study on breast cancer screening in Peru

Araujo¹,

Gómez²,

Jongh³

et al. 2023

ecancer

View full text Add to dashboard Cite

Introduction:A high prevalence of advanced breast cancer (BC) is a common scenario in Latin America. In Peru, the frequency of BC at Stages III/IV is ≈50% despite implementation of a programme for breast cancer screening (BCS) along the country. We carried out a study to assess the feasibility and develop an instrument to evaluate the knowledge, barriers and perception about BCS in a nationwide pilot study in Peru among candidates for BCS. Methods:We conducted a systematic review of 2,558 reports indexed in PubMed, Scopus, Web of Science, Medline-Ovid and EMBASE, regarding to our study theme. In total, 111 were selected and a 51-items survey was developed (eight items about sociodemographic characteristics). Patients were recruited in public hospitals or private clinics, in rural and urban areas of nine departments of Peru. Results:We surveyed 488 women from: Lima (150), Cajamarca (93), Ica (59), Arequipa (56), Loreto (48), Ancash (38), Junín (15), Puerto Maldonado (15) and Huancavelica (14); 27.9% of them were from rural areas. The mean of age was 53.3 years (standard deviation ± 9.1). Regarding education level, 29.8% had primary, 33.2% secondary and 37.0% higher education. In total, 28.7% of women did not know the term 'mammogram' and 47.1% reported never receiving a BCS (36.9% from urban and 73.5% from rural population). In women that underwent BCS, only 67% knew it is for healthy women. In total, 54.1% of patients had low levels of knowledge about risk factors for BC (i.e. 87.5% of women respond that injuries in the breast produce cancer). Cultural, economic and geographic barriers were significantly associated with having a mammogram where 56.9% of participants considered a cost ≤ 7 USD as appropriate. Mammogram was perceived as too painful for 54.9% of women. In addition, women with a self-perception of low-risk for BC and a fatalistic perception of cancer were less likely to have a BCS. Conclusion:We found that it is feasible to conduct a large-scale study in Peru. The results of this pilot study highlight an urgent need of extensive education and awareness about BCS in Peru.

show abstract

“…Similar to these findings, a study in public cancer hospitals in Peru found that of the 98 patients who died: 73.5% died from cancer progression, 18.4% from COVID-19, and 8.1% from undetermined causes; advanced disease stage and discontinuation of therapy were risk factors. [ 24 ]. A cohort study in Belgium found an excess of 50 prostate cancer deaths and an expected excess of 105 deaths in April 2020 [ 5 ].…”

Section: Discussionmentioning

confidence: 99%

“…Another cohort study in England found excess 1-year mortalities in prostate cancer patients during the COVID-19 pandemic [ 25 ]. Similarly, since the lockdown was introduced across Peru in 2020, considering the overstretched health care system, rescheduling of treatments and diagnostic procedures in oncological patients occurred [ 10 , 24 ]. There was an increase in the mortality rate of prostate cancer compared to previous years because of this, and, hence, an excess of mortality from prostate cancer.…”

Section: Discussionmentioning

confidence: 99%

Estimating Excess Mortality Due to Prostate, Breast, and Uterus Cancer during the COVID-19 Pandemic in Peru: A Time Series Analysis

Ramírez-Soto

Salazar-Peña

Vargas-Herrera

2023

IJERPH

View full text Add to dashboard Cite

During the COVID-19 pandemic, most of the deaths in Peru were related to COVID-19; however, cancer deaths have also been exacerbated in the first months of the pandemic. Despite this, excess mortalities of prostate, breast, and uterus cancer are not available by age group and region from January to December 2020. Therefore, we estimated the excess deaths and excess death rates (per 100,000 habitants) due to prostate, breast, and uterus cancer in 25 Peruvian regions. We did a time series analysis. Prostate, breast, and uterus cancer death data for 25 Peruvian regions were retrieved during the COVID-19 pandemic in 2020, as well as data for up to 3 years prior (2017–2019) from the Sistema Informatico Nacional de Defunciones at the Ministry of Health of Peru. Deaths in 2020 were defined as observed deaths. The expected deaths (in 2020) were estimated using the average deaths over 3 preceding years (2017, 2018 and 2019). Excess mortality was calculated as the difference between observed mortality and expected mortality in 2020. We estimated that the number of excess deaths and the excess death rates due to prostate, breast, and uterus cancer were 610 deaths (55%; 12.8 deaths per 100,000 men), 443 deaths (43%; 6 deaths per 100,000 women), and 154 deaths (25%; 2 deaths per 100,000 women), respectively. Excess numbers of deaths and excess death rates due to prostate and breast cancer increased with age. These excess deaths were higher in men aged ≥ 80 years (596 deaths (64%) and 150 deaths per 100,000 men) and women aged 70–79 years (229 deaths (58%) and 15 deaths per 100,000 women), respectively. In summary, during the COVID-19 pandemic, there were excess prostate and breast cancer mortalities in 2020 in Peru, while excess uterus cancer mortalities were low. Age-stratified excess death rates for prostate cancer and breast cancer were higher in men ≥ 80 years and in women ≥ 70 years, respectively.

show abstract

Oncological Care During First Peruvian National Emergency COVID-19 Pandemic: A Multicentric Descriptive Study

Cited by 6 publications

References 30 publications

Effects of the COVID-19 pandemic on elderly patients with head and neck squamous cell carcinoma

Effects of the COVID-19 pandemic on elderly patients with head and neck squamous cell carcinoma

A nationwide pilot study on breast cancer screening in Peru

Estimating Excess Mortality Due to Prostate, Breast, and Uterus Cancer during the COVID-19 Pandemic in Peru: A Time Series Analysis

Contact Info

Product

Resources

About